Cytokinetics (CYTK) is up 34.2%, or $12.09 to $47.42.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $84 from $77 at Citi
- Buy Rating for Cytokinetics: Aficamten Shows Promising Results in Hypertrophic Cardiomyopathy Trials
- Cytokinetics’ Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results
- Cytokinetics presents additional data from MAPLE-HCM study
- Cytokinetics announces primary results from MAPLE-HCM trial